A real-time quantitative PCR targeting the viral vector for the monitoring of patients treated with axicabtagene ciloleucel

Axicabtagene ciloleucel or axi-cel (CD19-CAR T-cells) has been recently approved for refractory/ relapsed diffuse large B cell lymphoma and primary mediastinal B-cell lymphoma. Proliferation of CAR T-cells after infusion and their persistence have been reported as important factors. Laboratory tools are needed for the monitoring of patients.We developed a vector-based, simple and accurate real-time qPCR to measure axi-cel vector copy number (VCN) in peripheral blood samples.Primers and probe targeting the 5 ’LTR region of the gammaretroviral vector (mouse stem cell virus or MSCV) were designed for amplification.

Source: Journal of Molecular Diagnostics - December 29, 2020 Category: Pathology Authors: Agathe Baras, Laurence Bocket, David Beauvais, Christophe Hallaert, Pauline Varlet, Ibrahim Yakoub Agha, Didier Hober, Enagnon Kazali Alidjinou Source Type: research